Status:

ACTIVE_NOT_RECRUITING

Vitamin D and Omega-3 Trial (VITAL)

Lead Sponsor:

Brigham and Women's Hospital

Collaborating Sponsors:

National Cancer Institute (NCI)

National Heart, Lung, and Blood Institute (NHLBI)

Conditions:

Cancer

Cardiovascular Disease

Eligibility:

All Genders

50+ years

Phase:

PHASE3

Brief Summary

The VITamin D and OmegA-3 TriaL (VITAL) is a randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acid...

Detailed Description

The VITamin D and OmegA-3 TriaL (VITAL) is a randomized clinical trial of vitamin D (in the form of vitamin D3 \[cholecalciferol\]) and marine omega-3 fatty acid (eicosapentaenoic acid \[EPA\] + docos...

Eligibility Criteria

Inclusion

  • To be eligible for the study, respondents had to, at study entry,:
  • be men aged 50 or older or women aged 55 or older;
  • have no history of cancer (except non-melanoma skin cancer), heart attack, stroke, transient ischemic attack, angina pectoris, coronary-artery bypass grafting, or percutaneous coronary intervention;
  • have none of the following safety exclusions: history of renal failure or dialysis, hypercalcemia, hypo- or hyperparathyroidism, severe liver disease (cirrhosis), or sarcoidosis or other granulomatous diseases such as active chronic tuberculosis or granulomatosis with polyangiitis (Wegener's);
  • have no allergy to fish or soy;
  • have no other serious illness that would preclude participation;
  • be consuming no more than 800 IU of vitamin D from all supplemental sources combined (individual vitamin D supplements, calcium+vitamin D supplements, medications with vitamin D \[e.g., Fosamax Plus D\], and multivitamins), or, if taking, willing to decrease or forego such use during the trial;
  • be consuming no more than 1200 mg/d of calcium from all supplemental sources combined, or, if taking, willing to decrease or forego such use during the trial;
  • not be taking fish oil supplements, or, if taking, willing to forego their use during the trial

Exclusion

    Key Trial Info

    Start Date :

    July 1 2010

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 1 2026

    Estimated Enrollment :

    25871 Patients enrolled

    Trial Details

    Trial ID

    NCT01169259

    Start Date

    July 1 2010

    End Date

    May 1 2026

    Last Update

    November 6 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Brigham and Women's Hospital

    Boston, Massachusetts, United States, 02215